Xiao–Tang Kong

917 total citations
51 papers, 679 citations indexed

About

Xiao–Tang Kong is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiao–Tang Kong has authored 51 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 14 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiao–Tang Kong's work include Glioma Diagnosis and Treatment (24 papers), Cancer Research and Treatments (10 papers) and Brain Metastases and Treatment (8 papers). Xiao–Tang Kong is often cited by papers focused on Glioma Diagnosis and Treatment (24 papers), Cancer Research and Treatments (10 papers) and Brain Metastases and Treatment (8 papers). Xiao–Tang Kong collaborates with scholars based in United States, Japan and China. Xiao–Tang Kong's co-authors include Eric J. Stanbridge, Oscar Aurelio, Swati Gupta, Cheng‐Hu Hu, Y. Ding, Yan Jin, Xiaoli Chen, Daniela A. Bota, Frank P. K. Hsu and Gabriel Arismendi-Morillo and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiao–Tang Kong

37 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiao–Tang Kong United States	12	339	190	180	109	94	51	679
Daniela Belloni Italy	16	362 1.1×	234 1.2×	99 0.6×	152 1.4×	188 2.0×	27	810
Tomoko Uno Japan	10	254 0.7×	114 0.6×	225 1.3×	132 1.2×	278 3.0×	11	647
Cristiana Lavazza Italy	15	300 0.9×	97 0.5×	192 1.1×	92 0.8×	52 0.6×	33	573
Grazia Abou‐Ezzi United States	10	314 0.9×	138 0.7×	101 0.6×	190 1.7×	157 1.7×	13	614
Yali Xu China	15	428 1.3×	93 0.5×	125 0.7×	52 0.5×	73 0.8×	44	783
Dalia Arafat United States	13	233 0.7×	74 0.4×	218 1.2×	133 1.2×	46 0.5×	24	612
Mario Ricciardi Italy	10	228 0.7×	161 0.8×	267 1.5×	111 1.0×	59 0.6×	15	700
Javier Cibella Italy	10	199 0.6×	101 0.5×	172 1.0×	204 1.9×	49 0.5×	15	549
Ulrich Rochwalsky Germany	5	461 1.4×	142 0.7×	123 0.7×	100 0.9×	53 0.6×	8	626
So Young Chong South Korea	15	637 1.9×	129 0.7×	135 0.8×	133 1.2×	184 2.0×	52	1.1k

Countries citing papers authored by Xiao–Tang Kong

Since Specialization

Citations

This map shows the geographic impact of Xiao–Tang Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao–Tang Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao–Tang Kong more than expected).

Fields of papers citing papers by Xiao–Tang Kong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao–Tang Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao–Tang Kong. The network helps show where Xiao–Tang Kong may publish in the future.

Co-authorship network of co-authors of Xiao–Tang Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao–Tang Kong. A scholar is included among the top collaborators of Xiao–Tang Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao–Tang Kong. Xiao–Tang Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gettinger, Scott, Karen L. Reckamp, Jeffrey A. Moscow, et al.. (2024). Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology. 8(8). e2300725–e2300725. 2 indexed citations

Yuen, Carlen, et al.. (2024). A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an EGFR tyrosine kinase inhibitor-treated non-small-cell lung cancer patient. Biomarkers in Medicine. 18(9). 433–441.

Kong, Xiao–Tang, et al.. (2024). CTNI-81. PROPOSAL FOR A PHASE IB PILOT CLINICAL TRIAL TO STUDY SAFETY AND IMPROVING ANTI-NEOPLASTIC ADVERSE EFFECTS BY ADDITION OF NATURAL MARINE PRODUCT FUCOIDAN TO THE STANDARD THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology. 26(Supplement_8). viii116–viii116.

Yuen, Carlen, et al.. (2024). Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report. Personalized Medicine. 21(2). 71–78.

Yuen, Carlen, et al.. (2024). A High-Grade Glioma, Not Elsewhere Classified in an Older Adult with Discordant Genetic and Epigenetic Analyses. Biomedicines. 12(9). 2042–2042. 1 indexed citations

Kong, Xiao–Tang, et al.. (2023). IMMU-54. PNEUMOCYSTIS JIROVECII PNEUMONIA INFECTION IN A PATIENT WITH ANAPLASTIC ASTROCYTOMA AND RADIATION NECROSIS IN THE SETTING OF CORTICOSTEROID AND PEMBROLIZUMAB USE. Neuro-Oncology. 25(Supplement_5). v154–v155.

Bota, Daniela A., David Piccioni, Thomas H. Taylor, et al.. (2023). Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology. 41(16_suppl). 2047–2047. 1 indexed citations

Kong, Xiao–Tang, et al.. (2023). INNV-21. EXTENDED SURVIVAL OF RECURRENT ANAPLASTIC OLIGODENDROGLIOMA PATIENT WITH GOOD FUNCTIONAL STATUS ON LONG TERM PEMBROLIZUMAB AND BEVACIZUMAB THERAPY - A CASE REPORT. Neuro-Oncology. 25(Supplement_5). v161–v161.

Bota, Daniela A., Thomas H. Taylor, Naomi Lomeli, et al.. (2022). A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Frontiers in Oncology. 12. 934638–934638. 5 indexed citations

10.

Bota, Daniela A., et al.. (2022). Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy. Neurology International. 14(3). 574–580. 2 indexed citations

11.

Bota, Daniela A., Thomas H. Taylor, David Piccioni, et al.. (2022). Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. Journal of Experimental & Clinical Cancer Research. 41(1). 344–344. 38 indexed citations

12.

Farahabadi, Maryam Hosseini, et al.. (2020). Driving Out of Coma: Treatment of Anti-NMDA Receptor Encephalitis with Bortezomib (5437). Neurology. 94(15_supplement).

13.

Bota, Daniela A., Thomas Taylor, Xiao–Tang Kong, et al.. (2020). CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS. Neuro-Oncology. 22(Supplement_2). ii34–ii34.

14.

Bota, Daniela A., et al.. (2019). ATIM-42. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: OS CORRELATIONS WITH INITIAL AND MAXIMUM CD4+T LYMPHOCYTE COUNT IN THE PERIPHERAL BLOOD. Neuro-Oncology. 21(Supplement_6). vi10–vi11. 1 indexed citations

15.

Kong, Xiao–Tang. (2017). From “One-Size-Fits-All” to a precision medicine approach in neurooncology and neurology practice. Neurology and Clinical Neuroscience. 1(1). 1 indexed citations

16.

Tran, P. & Xiao–Tang Kong. (2017). Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia. Case Reports in Neurology. 9(1). 114–120. 7 indexed citations

17.

Kong, Xiao–Tang, et al.. (2014). Successful desensitization protocol for delayed cutaneous eruption to temozolomide. The Journal of Allergy and Clinical Immunology In Practice. 2(5). 626–628. 7 indexed citations

18.

Chen, Xiaoli, et al.. (2013). Nuclear factor-κB modulates osteogenesis of periodontal ligament stem cells through competition with β-catenin signaling in inflammatory microenvironments. Cell Death and Disease. 4(2). e510–e510. 102 indexed citations

19.

Aurelio, Oscar, Xiao–Tang Kong, Swati Gupta, & Eric J. Stanbridge. (2000). p53 Mutants Have Selective Dominant-Negative Effects on Apoptosis but Not Growth Arrest in Human Cancer Cell Lines. Molecular and Cellular Biology. 20(3). 770–778. 64 indexed citations

20.

Kong, Xiao–Tang, Virginia Valentine, Susan Rowe, et al.. (1999). Lack of Homozygously Inactivated p73 in Single-Copy MYCN Primary Neuroblastomas and Neuroblastoma Cell Lines. Neoplasia. 1(1). 80–89. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact